The Saudi Food and Drug Authority (SFDA) achieved a historic global healthcare milestone this week. Specifically, the regulatory body registered ZENBEXUS (iberdomide) for adult patients with relapsed or refractory multiple myeloma. Consequently, the SFDA became the first regulatory authority worldwide to authorize this innovative medicine. Attending doctors will prescribe ZENBEXUS in combination with daratumumab and dexamethasone.
Strategic Regulatory Leadership
Why it matters: This landmark decision places Saudi Arabia at the forefront of global oncology and pharmaceutical regulation. Consequently, Saudi patients gain immediate access to a next-generation therapy before any other nation. This strategic move directly supports the Kingdom’s Health Sector Transformation Program under the umbrella of Saudi Vision 2030. By prioritizing advanced medical solutions, the SFDA continues to enhance the quality of life for citizens across the entire Kingdom.
Multiple myeloma originates in plasma cells within the bone marrow. This severe blood cancer undermines patient health significantly across the globe. Furthermore, the disease causes debilitating anemia, low white blood cell counts, weakened immunity, impaired kidney function, and severe bone damage. Most adult cancer patients eventually experience disease relapse after initial therapies. Therefore, patients urgently require targeted therapies to overcome treatment resistance.
How it works:
- Developer Bristol Myers Squibb engineered ZENBEXUS as a cereblon E3 ligase modulator (CELMoD).
- The drug targets and degrades specific proteins that fuel cancer cell survival and growth.
- Simultaneously, the treatment enhances the body’s immune response to attack malignant plasma cells effectively.
- Consequently, this dual mechanism creates a powerful new therapeutic option for complex oncology cases.
- Indeed, CELMoD agents represent a major leap forward over traditional immunomodulatory treatments.
Clinical Trial Findings and Safety Guidance
By the numbers:
- Doctors diagnosed roughly 188,000 new multiple myeloma cases globally in 2022.
- Cases are projected to keep rising as populations age, including across the Gulf.
- The FDA set its own decision date for the same drug at 17 August, 2026.
The approval builds on the SFDA’s Breakthrough Medicine Program, which fast-tracks promising drugs for serious diseases. That head start lets Saudi patients access ZENBEXUS well before other major markets.
The US is still catching up. The FDA accepted Bristol Myers Squibb’s application for the same combination in February 2026. So, the SFDA’s approval lands months ahead of Washington’s.
What they are saying: The SFDA emphasized essential prescribing conditions alongside its official announcement. “Physicians must use this product under specialized medical supervision,” declared the regulatory authority. Furthermore, healthcare providers must conduct regular clinical evaluations and blood tests in accordance with approved prescribing guidelines.
Additionally, the prescribing leaflet provides comprehensive safety protocols and dosing instructions for attending medical staff. Therefore, strict clinical supervision protects overall patient wellbeing throughout the entire cancer treatment process.
Advancing Vision 2030 Healthcare Ambitions
Between the lines: The SFDA previously designated ZENBEXUS under its Breakthrough Medicine Program. This strategic initiative accelerates patient access to specialized treatments within Saudi Arabia. Moreover, the program accepts advanced candidate medicines that demonstrate clear therapeutic efficacy against serious illnesses. Importantly, eligible therapeutics must not hold prior approvals from other international regulatory agencies. Thus, Saudi Arabia secures early access to groundbreaking therapies for its citizens before other global markets.
Saudi Arabia continues to establish fast-track regulatory mechanisms to attract global pharmaceutical innovation. Specifically, the SFDA maintains compressed scientific assessment timelines for designated breakthrough medicines. Consequently, international pharmaceutical developers increasingly prioritize Saudi Arabia for initial drug registration applications worldwide.
The bottom line: This landmark regulatory decision highlights the Kingdom’s growing influence in global pharmaceutical oversight. Additionally, the approval aligns directly with the Health Sector Transformation Program under Saudi Vision 2030. As a direct result, Saudi Arabia continues to transform its national healthcare ecosystem, improve clinical outcomes significantly, and expand equitable public access to innovative modern medical oncology solutions.
What’s next: Saudi patients with limited options can start treatment today, under medical supervision. That gives the Kingdom a head start in one of oncology’s most closely watched drug categories, and rare good news for Gulf families facing a myeloma diagnosis.
